Jacob Kilstein

United Therapeutics Corporation (NASDAQ: UTHR) reported its 1Q16 revenue and EPS short of consensus expectations. Argus’ Jacob Kilstein downgraded the rating for the company from Buy to Hold citing the challenging outlook. United Therapeutics reported its 1Q16 revenue at $369 million, up...

Argus’ Jacob Kilstein reiterated a Buy rating on Metlife Inc (NYSE: MET), while lowering the price target from $62 to $54. “Our rating reflects the stock’s attractive valuation, as well as the company’s global initiatives and efforts to return cash to shareholders,...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) shares have declined 16.09 percent over the past six months, ending Wednesday's session at $57.70. Argus’ Jacob Kilstein has maintained a Buy rating on the company, while lowering the price target from $82 to $75. Kilstein...

The share price of Eli Lilly and Co (NYSE: LLY) has appreciated 16.59 percent over the past year, from $69.74 on January 15, 2015. Argus’ Jacob Kilstein has reiterated a Buy rating and $93 price target on the company. Kilstein believes that the company has a solid late-stage...